Tema Etfs LLC Buys New Shares in Edwards Lifesciences Co. (NYSE:EW)

Tema Etfs LLC purchased a new position in Edwards Lifesciences Co. (NYSE:EW) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 21,635 shares of the medical research company’s stock, valued at approximately $1,602,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in Edwards Lifesciences by 10.4% in the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock worth $5,117,845,000 after purchasing an additional 6,537,494 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Edwards Lifesciences by 5.3% during the fourth quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company’s stock worth $2,458,601,000 after buying an additional 1,678,154 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Edwards Lifesciences by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company’s stock worth $1,007,520,000 after buying an additional 126,194 shares in the last quarter. Fisher Asset Management LLC increased its holdings in shares of Edwards Lifesciences by 7.7% during the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company’s stock worth $723,664,000 after buying an additional 696,965 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth approximately $610,895,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on EW. Morgan Stanley raised their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 12th. Truist Financial lowered their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating for the company in a report on Friday, April 11th. Evercore ISI lowered their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a report on Wednesday, February 12th. Piper Sandler raised their price target on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the company an “overweight” rating in a report on Tuesday, May 13th. Finally, StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Friday. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $79.60.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total value of $645,620.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,189,770.56. The trade was a 16.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction on Friday, February 28th. The shares were sold at an average price of $70.78, for a total transaction of $796,275.00. Following the completion of the sale, the chief financial officer now owns 30,387 shares in the company, valued at $2,150,791.86. The trade was a 27.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 66,192 shares of company stock valued at $4,709,454 over the last three months. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Trading Up 1.3%

Shares of NYSE EW opened at $77.92 on Friday. The company’s fifty day moving average is $72.08 and its 200-day moving average is $71.75. The stock has a market cap of $45.71 billion, a price-to-earnings ratio of 11.18, a P/E/G ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $95.25. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.60 by $0.04. The company had revenue of $1.41 billion for the quarter, compared to analysts’ expectations of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period last year, the firm posted $0.66 earnings per share. Equities research analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.